



# ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction

## Clinical Standards Committee

The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) is a scientific organization that encourages sound clinical practice, and high-quality teaching and research related to diagnostic imaging in women's healthcare. The ISUOG Clinical Standards Committee (CSC) has a remit to develop Practice Guidelines and Consensus Statements as educational recommendations that provide healthcare practitioners with a consensus-based approach, from experts, for diagnostic imaging. They are intended to reflect what is considered by ISUOG to be the best practice at the time at which they are issued. Although ISUOG has made every effort to ensure that Guidelines are accurate when issued, neither the Society nor any of its employees or members accepts any liability for the consequences of any inaccurate or misleading data, opinions or statements issued by the CSC. The ISUOG CSC documents are not intended to establish a legal standard of care, because interpretation of the evidence that underpins the Guidelines may be influenced by individual circumstances, local protocol and available resources. Approved Guidelines can be distributed freely with the permission of ISUOG (info@isuog.org).

## INTRODUCTION

The evaluation of fetal growth is one of the key objectives of prenatal care. Fetal growth depends on several factors, including uteroplacental function, maternal disease, maternal cardiovascular function or cardiac disease, maternal nutrition, altitude, smoking and illicit drug use, and presence of pathological conditions, such as infection, aneuploidy and some genetic conditions. However, uteroplacental insufficiency or dysfunction represents one of the most frequent causes of abnormal growth in an otherwise normal fetus.

Impaired fetal growth is associated with an increased risk of perinatal mortality and morbidity, and long-term adverse infant outcome<sup>1</sup>. Overall, growth-restricted fetuses have a higher rate of conditions associated with prematurity<sup>2</sup>, experience worse neurodevelopmental outcome and are at increased risk of non-communicable

diseases in adulthood, such as hypertension, metabolic syndrome, insulin resistance, Type-2 diabetes mellitus, coronary heart disease and stroke<sup>3</sup>. Prenatal recognition of fetal growth restriction (FGR) is a major factor identified in strategies aimed at preventing stillbirth, in which up to 30% of cases are associated with FGR or small-for-gestational age (SGA) in the late third trimester<sup>4,5</sup>.

This Guideline provides definitions of FGR, previously referred to as intrauterine growth restriction, and SGA, and describes the best possible management options based on current data and knowledge. For the purposes of this Guideline, we assume that the pregnancy is singleton, pregnancy dating has been carried out correctly (preferably in the first trimester by ultrasound) and that there are no fetal pathologies, such as aneuploidy, congenital malformation or infection. Details of the grades of recommendation used in this Guideline are provided in Appendix 1. Reporting of levels of evidence is not applicable to this Guideline.

## GUIDELINE

### Definition of and distinction between small-for-gestational age and fetal growth restriction

Fetal growth is a dynamic process and its assessment requires multiple observations of fetal size over time. Fetal size is determined through biometric evaluation of the head circumference, biparietal diameter, abdominal circumference (AC) and femur length and/or derivation of estimated fetal weight (EFW) computed by different formulae. The ISUOG Guidelines on ultrasound assessment of fetal biometry and growth describe methodology, reference ranges, growth standards and quality-control processes for appropriate assessment of fetal biometry and diagnosis of fetal growth disorders<sup>6</sup>. Controversies in relation to reference ranges and other issues related to the assessment of fetal biometry are described in this Guideline.

A fetus is considered to be SGA when its size (biometric evaluation) falls below a predefined threshold for its gestational age. The most common definition of SGA is EFW or AC below the 10<sup>th</sup> percentile of given

reference ranges. Nevertheless, other thresholds have been described, such as the 5<sup>th</sup> and 3<sup>rd</sup> percentiles (the latter approximating to 2 SD) or a Z-score of  $-2$ .

FGR is a condition that is frequently, but unhelpfully, defined as the fetus failing to reach its genetically predetermined growth potential. The identification of FGR is often not straightforward as fetal growth cannot be assessed through a single biometric evaluation of the fetal size, and growth potential is hypothetical.

The main distinction between SGA and FGR is that a SGA fetus may be small but not at increased risk of adverse perinatal outcome, while a fetus with size above the 10<sup>th</sup> percentile may be FGR and at increased risk of adverse perinatal and long-term outcome<sup>7–11</sup>.

Fetuses with birth weight below the 10<sup>th</sup> percentile are at increased risk of stillbirth<sup>12</sup> and perinatal mortality<sup>13–15</sup>, with those with birth weight below the 3<sup>rd</sup> percentile being at the highest risk<sup>12,13</sup>. For this reason, fetal size at the lower extreme of the growth charts, for example AC or EFW below the 3<sup>rd</sup> percentile for given growth charts, can be used as an isolated criterion to define FGR at any gestational epoch<sup>16</sup>. However, the optimal size at birth that is associated with the lowest perinatal mortality seems to be substantially higher than the median birth weight of a normal cohort<sup>13</sup>. In fact, a population-based cohort study found increased perinatal mortality even in fetuses with birth weight within the normal range, with those with birth weight between the 70<sup>th</sup> and 90<sup>th</sup> percentiles being at the lowest risk, and an inverse association between perinatal mortality and birth weight below the 80<sup>th</sup> percentile<sup>13</sup>. A large Scottish population-based cohort study demonstrated a progressive increase in the risk of stillbirth in pregnancies with a predicted birth weight below the 25<sup>th</sup> percentile<sup>17</sup>.

In order to differentiate between SGA and FGR in cases in which the fetal size is below the 10<sup>th</sup> percentile, additional biophysical parameters are required. Many methods have been proposed for this purpose, such as evaluation of fetal growth velocity, use of customized growth charts, Doppler velocimetric evaluation of placental and fetal circulations and use of biomarkers. Some of these biophysical parameters are also used to monitor fetal status and/or as delivery decision criteria (e.g. umbilical artery (UA) Doppler). Biophysical tools, such as ductus venosus velocimetry, biophysical profile (BPP) scoring and cardiotocographic (CTG) assessment of fetal heart rate short-term variation (STV), are not used as diagnostic criteria for FGR but for the surveillance and management of pregnancies already diagnosed as FGR, and are discussed below.

## Tools for diagnosis, surveillance and management of fetal growth restriction

### *Fetal growth velocity*

There are several methods to evaluate fetal growth velocity, including use of longitudinal growth charts<sup>18</sup>, assessment of deviation from growth-velocity charts<sup>18</sup> and

individualized growth assessment<sup>19</sup>. Overall, the objective is to evaluate the fetal growth trajectory and identify those fetuses that are deviating from their individual trajectory, indicating a failure to reach their growth potential. There is evidence to suggest that reduced fetal growth velocity in the third trimester is associated with increased risk of adverse outcome<sup>11,20</sup>. Reduced growth velocity is normally taken to be a fall between consecutive ultrasound scans of  $> 50$  percentiles for AC or, more commonly, EFW<sup>6</sup>.

### *Customized growth charts*

In customized charts, the fetal weight and growth are adjusted for variables known to impact fetal size. These can include maternal height, weight, age, parity and ethnicity and fetal sex. Adjustment for these variables is suggested to allow for better identification of SGA fetuses at risk of perinatal complications<sup>6</sup>. Methods to evaluate fetal growth velocity and application of customized growth charts for this purpose are described in more detail in the ISUOG Guidelines on ultrasound assessment of fetal biometry and growth<sup>6</sup>.

### *Doppler velocimetry*

The rationale behind the application of Doppler velocimetry in fetal growth assessment is that it can identify uteroplacental function through evaluation of the uterine and umbilical arteries. Uteroplacental insufficiency is putatively mediated through spiral artery maladaptation and alterations in the villous vascular tree. On the fetal side, Doppler velocimetry allows evaluation of the middle cerebral artery (MCA) and ductus venosus as fetal cardiovascular adaptation progresses from hypoxia to acidemia.

A lack of physiological transformation of the uterine arteries from high- to low-resistance vessels is thought to reflect inadequate trophoblastic invasion of the spiral arteries, leaving a high-resistance circulation. The persistence of high uterine artery mean pulsatility index (PI) (above the 95<sup>th</sup> percentile) is associated with placental insufficiency and maternal vascular malperfusion of the placenta<sup>21</sup>.

Progressively increasing PI in the UA corresponds to a progressive reduction in the placental surface area available for gas and nutrient exchange and increased fetal afterload resistance, and is associated with placental vascular insufficiency reflected by absent and, in the end-stage phase, reversed end-diastolic flow (EDF) in the UA<sup>22</sup>.

Reduced fetal MCA-PI is a consequence of vasodilatation, the so called 'brain-sparing' effect. This represents a hemodynamic response to fetal hypoxemia, via direct vascular sensing of oxygen tension in the cerebral circuit, and in other vascular beds a consequent redistribution of fetal cardiac output occurs preferentially to the coronary arteries and adrenal glands<sup>23</sup>.

Alterations in the ductus venosus flow velocity waveform, especially absent or reversed a-wave, are

caused by progressive dilatation of the ductus venosus isthmus in order to increase the blood flow toward the heart, in an attempt to compensate for extreme oxygen deprivation<sup>24</sup>. Others consider that absent or reversed a-wave in the ductus venosus is a consequence of increased intra-atrial pressure due to high cardiac afterload (increased vascular placental resistance) and/or a direct effect of fetal acidemia on myocardial cell function<sup>25</sup>.

Doppler velocimetry plays a central role in identification, surveillance and management of FGR, because it allows for the identification of uteroplacental insufficiency and/or fetal cardiovascular adaptation to hypoxemia. Importantly, the two phenotypes of FGR, early-onset and late-onset, are characterized by different Doppler velocimetry patterns, as discussed below.

### *Biophysical profile scoring*

The BPP score consists of the combined evaluation of fetal tone, gross body movement, breathing movement, amniotic fluid volume and heart-rate reactivity. BPP score can predict both fetal pH and outcome<sup>26,27</sup>. The relationship between altered BPP score and fetal pH seems to be consistent across gestational ages<sup>26</sup>. A score of  $\leq 4$  is associated with a fetal pH  $\leq 7.20$ , while a score of  $< 2$  has a sensitivity of 100% for acidemia<sup>27</sup>. This correlation remains highly significant even when using a simplified BPP that is based on assessment of only fetal heart rate and amniotic fluid volume<sup>28</sup>.

### *Cardiotocography and short-term variation*

A reactive CTG virtually excludes fetal hypoxemia. The fetal heart rate STV is a biophysical parameter obtained by computerized CTG (cCTG) that reflects autonomic nervous system function. In the context of FGR and the accompanying presence of severe hypoxemia or hypoxia, the fetal sympathetic and parasympathetic activity is altered, resulting in reduced fetal heart rate variation, and, thus, reduced STV.

cCTG and evaluation of STV have been validated against invasive testing in fetal hypoxemia and acidemia and represent the only objective measure of fetal heart rate<sup>29</sup>. Visual inspection of conventional CTG does not provide the same information as cCTG, as CTG represents a largely subjective assessment with low intra- and interobserver reproducibility.

### *Biomarkers*

Placental biomarkers have a potential role in screening, diagnosis and therapy of placental disease linked to hypertensive disorders of pregnancy and/or FGR<sup>30</sup>. Several placental factors have been investigated, including placental proteins as well as microRNA and mRNA. Some placental proteins, such as pregnancy-associated plasma protein-A, are biomarkers of placental function in the first trimester, though its predictive ability is limited<sup>31,32</sup>.

The soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) ratio has been proposed as a short-term predictor to rule out pre-eclampsia in women in whom this condition is suspected clinically<sup>33</sup>. Although some reports suggest that use of the sFlt-1/PlGF ratio might be helpful in the management of and differentiation between SGA and FGR<sup>34–38</sup>, the lack of interventional trial data precludes the recommendation of these tests as an adjunct to ultrasound imaging. The rapidly evolving research-based discussion of the use of biomarkers in screening for SGA and FGR is beyond the scope of this Guideline.

### *Recommendations*

- Fetal size alone is not sufficient to identify FGR, unless AC or EFW is below the 3<sup>rd</sup> percentile (**GRADE OF RECOMMENDATION: C**).
- A drop in fetal growth velocity, i.e. drop in AC or EFW of  $> 2$  quartiles or  $> 50$  percentiles (e.g. from 70<sup>th</sup> percentile to or below 20<sup>th</sup> percentile), should alert the physician to possible FGR (**GRADE OF RECOMMENDATION: C**).
- Doppler velocimetry of the uteroplacental and fetoplacental circulations may be used to distinguish between SGA and FGR (**GOOD PRACTICE POINT**).
- Multimodal assessment is recommended for the evaluation of pregnancies with suspected FGR. cCTG or BPP scoring should be used in combination with Doppler velocimetry (**GRADE OF RECOMMENDATION: A**).

### **Definition of early-onset and late-onset fetal growth restriction**

There are two main phenotypes of FGR which differ significantly in many aspects, such as prevalence, prediction by first-trimester ultrasound, gestational age at onset, placental histopathological findings, Doppler velocimetric profile, maternal associated disease, severity and perinatal outcome. Table 1 presents the main characteristics of the two phenotypes, which are defined as early-onset and late-onset FGR based on the observation that one phenotype is more frequent in early gestation and the second near term<sup>39–42</sup>.

The distinction between early and late FGR is usually based on diagnosis before or after 32–34 weeks' gestation. Although UA Doppler evaluation seems to discriminate better than gestational age between the two phenotypes of FGR with regards to their association with pre-eclampsia and adverse perinatal outcome<sup>39,40</sup>, 32 weeks seems to be the optimal gestational-age cut-off at diagnosis and provides a reasonable classification of the two FGR phenotypes<sup>40</sup>. This gestational-age threshold, therefore, is largely agreed upon as the main criterion to differentiate between early and late FGR<sup>16</sup> and is used to distinguish between early- and late-onset FGR in this Guideline.

The definition of FGR varies between different guidelines and author groups<sup>43</sup>. The criteria proposed

**Table 1** Main clinical characteristics of early- and late-onset fetal growth restriction (FGR)

Characteristic	Early-onset FGR	Late-onset FGR
Main clinical challenge	Management	Detection
Prevalence	30%	70%
Gestational age at manifestation	< 32 weeks	≥ 32 weeks
Ultrasound findings	Fetus may be very small	Fetus not necessarily very small
Doppler velocimetry	Spectrum of Doppler alterations that involves umbilical artery, middle cerebral artery and ductus venosus	Cerebral blood-flow redistribution
Biophysical profile	May be abnormal	May be abnormal
Hypertensive disorders of pregnancy	Frequent	Not frequent
Placental histopathological findings	Poor placental implantation, spiral artery abnormalities, maternal vascular malperfusion	Less specific placental findings, mainly altered diffusion
Perinatal mortality	High	Low
Maternal cardiovascular hemodynamic status	Low cardiac output, high peripheral vascular resistance	Less marked maternal cardiovascular findings

**Table 2** Definitions for early- and late-onset fetal growth restriction (FGR) in absence of congenital anomalies, based on international Delphi consensus

Early FGR: GA < 32 weeks, in absence of congenital anomalies	Late FGR: GA ≥ 32 weeks, in absence of congenital anomalies
AC/EFW < 3 <sup>rd</sup> centile or UA-AEDF Or 1. AC/EFW < 10 <sup>th</sup> centile combined with 2. UtA-PI > 95 <sup>th</sup> centile and/or 3. UA-PI > 95 <sup>th</sup> centile	AC/EFW < 3 <sup>rd</sup> centile Or at least two out of three of the following 1. AC/EFW < 10 <sup>th</sup> centile 2. AC/EFW crossing centiles > 2 quartiles on growth centiles* 3. CPR < 5 <sup>th</sup> centile or UA-PI > 95 <sup>th</sup> centile

\*Growth centiles are non-customized centiles. AC, fetal abdominal circumference; AEDF, absent end-diastolic flow; CPR, cerebroplacental ratio; EFW, estimated fetal weight; GA, gestational age; PI, pulsatility index; UA, umbilical artery; UtA, uterine artery. Reproduced from Gordijn *et al.*<sup>16</sup>.

by an international Delphi consensus represent the most recognized definition of FGR (Table 2)<sup>16</sup>. In a recent validation study, the performance of these criteria was compared to that of a FGR definition of EFW < 10<sup>th</sup> percentile using the Hadlock growth standard, in predicting adverse neonatal outcome<sup>44</sup>. The study cohort spanned a wide gestational-age range and the two definitions had comparable performance, though the Delphi criteria were associated with an improved prediction of adverse neonatal outcome.

### Recommendations

- The two main phenotypes of FGR, early and late, are characterized by different clinical, ultrasound and pathological characteristics (**GRADE OF RECOMMENDATION: D**).
- The authors of this ISUOG guideline recommend the Delphi consensus criteria<sup>16</sup> for definition of FGR (**GOOD PRACTICE POINT**).

### Doppler velocimetry

Despite the fact that Doppler velocimetry has been used in obstetric practice for nearly four decades, there is no universal agreement on which indices, thresholds and/or reference ranges to use. These considerations are not

applicable when qualitative assessment is performed, such as evaluation of absent/reversed ductus venosus a-wave or absent/reversed EDF in the UA, but they affect Doppler velocimetry quantitative evaluation. International guidance on how to perform uteroplacental and fetal Doppler velocimetry is provided by ISUOG<sup>45</sup>.

There is considerable methodological heterogeneity in studies reporting reference ranges for MCA and UA Doppler indices and their ratio, which may, at least partly, explain the differences in reported reference ranges<sup>46</sup>. Even among studies with a high methodological quality score, there are significant differences in the definition of 'normality' and normal ranges<sup>46</sup>. A recent study evaluating the 10 most-cited articles providing reference ranges for MCA-PI, UA-PI and cerebroplacental ratio (CPR), found wide discrepancies in Doppler reference values that accounted for a variability of up to 50% in the 5<sup>th</sup> percentile cut-off value of MCA-PI at term<sup>47</sup>. Similarly, the study found significant differences in the cut-off for UA-PI above the 95<sup>th</sup> percentile (20–40%) and CPR below the 5<sup>th</sup> percentile (15–35%)<sup>47</sup>. Wide discrepancies have been reported in reference ranges used for biometry, Doppler parameters and birth weight, even at national level in centers with high expertise in the management of FGR, that might significantly impact the diagnosis and management of FGR<sup>48</sup>.



Another reason for the lack of standardization of quantitative Doppler velocimetry is that there is no uniformity in Doppler indices that are used, especially in research studies. For example, cerebral blood-flow redistribution can be defined as MCA-PI below different percentile thresholds (5<sup>th</sup> or 10<sup>th</sup> percentile), Z-scores or multiples of the median (MoM), or it can be defined as umbilicocerebral ratio (UCR) or CPR above or below different percentile thresholds, Z-scores or MoM, respectively<sup>49</sup>. The Delphi consensus procedure identified CPR below the 5<sup>th</sup> percentile and UA-PI above the 95<sup>th</sup> percentile as Doppler criteria to define FGR<sup>16</sup>. The rationale behind the application of the ratios of MCA-PI and UA-PI (CPR and UCR), instead of the individual components, is that they have been shown to be more sensitive to fetal hypoxia<sup>50</sup> and to be associated more strongly with adverse perinatal outcome<sup>49,51</sup>. CPR is reported in studies more frequently than is UCR. A recent study suggested that UCR may allow for better differentiation of cases in the abnormal range in early FGR, as compared with CPR<sup>52</sup>. However, it should be highlighted that there is no strong evidence in favor of either ratio.

The high variability in Doppler reference ranges and indices used has a major clinical impact on prenatal diagnosis, monitoring, timing of delivery decision, reproducibility and comparison of findings between research studies, efficacy of clinical policies and protocols, and many other aspects<sup>46</sup>. The discussion about which reference ranges to use for the diagnosis and management of FGR is beyond the scope of this Guideline. However, these differences should be acknowledged and action is needed to homogenize the adoption of Doppler indices, thresholds and reference ranges in clinical and research practice. Table S1 summarizes the most relevant studies reporting reference charts for MCA and its ratios.

### Early-onset fetal growth restriction

Early FGR is particularly associated with maternal vascular malperfusion of the placenta, characterized by abnormal transformation of the spiral arteries, pathologic features of the placental villi and multifocal infarction; these disease components result in so-called 'placental insufficiency' and form the most common basis for placenta-mediated FGR<sup>53,54</sup>. Chronic ischemia of the placental villi impairs PlGF secretion and leads to excessive sFlt-1 release by syncytial knots, thus resulting in elevated sFlt-1/PlGF ratio which typifies early FGR and the associated hypertensive disorders of pregnancy<sup>34–38</sup>. Elevated Doppler UA-PI typically precedes a cascade of Doppler alterations, fetal heart rate changes and BPP modifications, with end-stage cardiovascular deterioration caused by severe hypoxemia followed by acidosis<sup>55–57</sup>. **Uterine artery, UA and MCA Doppler abnormalities represent early changes in early FGR** and may be present for many weeks before severe cardiovascular and metabolic deterioration occurs. Although **absent UA-EDF represents a progressive**

**deterioration of uteroplacental function, it still precedes critical fetal deterioration, and the progression to reversed UA-EDF might be slow.** However, the rate and rapidity of alteration in UA Doppler, from increased blood-flow resistance to absent EDF, determines the rate of fetal deterioration<sup>56,58</sup>. **The late deterioration in early FGR characterized by severe placental insufficiency is reflected by reversal of the EDF in the UA, and worsening generalized cardiovascular and metabolic failure reflected by alterations in the ductus venosus (absent or reversed a-wave)**<sup>57,59</sup>. This cardiovascular deterioration might precede or occur in parallel with the alteration of the STV, eventually manifesting as abnormal BPP score, spontaneous repetitive decelerations on CTG and stillbirth<sup>39,60</sup>.

At present, there is no effective therapy for early FGR, though efficient recognition and management of severe pre-eclampsia may prolong some pregnancies with early FGR. The timely use of steroids, followed by magnesium sulfate, transfer to a tertiary care center and consideration of the safest mode of delivery, are the key concepts in early-FGR management<sup>61</sup>. Ultimately, delivery represents the only therapeutic option in early FGR, in order to prevent severe consequences from hypoxia and acidosis that can lead to perinatal morbidity and mortality. On the other hand, the decision to deliver has to be balanced against the possible harm caused by prematurity<sup>62,63</sup>. This is further complicated by the fact that the fetus is suffering from growth restriction, which is an independent risk factor for adverse outcomes associated with prematurity, thus making the outcome even more unfavorable<sup>64,65</sup>. This is highlighted by the fact that, in fetuses with early FGR, neonatal survival first exceeds 50% after 26 weeks' gestation, which is 2 weeks later than in their appropriate-for-gestational-age (AGA) counterparts<sup>55</sup>. In this view, optimal monitoring and timing of delivery are of crucial importance when managing early FGR.

### How to monitor

Once early FGR is suspected/diagnosed, the pregnancy should be monitored and managed in tertiary-level fetal medicine and neonatal units according to a uniform management protocol<sup>66</sup>. Multidisciplinary counseling by neonatology and maternal–fetal medicine specialists is important. Evidence from a randomized trial (Trial of Randomized Umbilical and Fetal Flow in Europe (TRUFFLE)) shows that monitoring and delivery timing according to a specific protocol including ductus venosus Doppler and cCTG provides better-than-expected outcomes<sup>66</sup>. It should be taken into account that cCTG is not available or used universally. In that case, in addition to Doppler evaluation, assessment of conventional CTG and, where undertaken, BPP scoring should be performed<sup>27</sup>. The loss of fetal gross body movement in association with ductus venosus Doppler index alterations can predict fetal cord pH < 7.20, while loss of fetal tone is associated with pH < 7.00 or a base excess < –12 mEq/L<sup>27</sup>.

The surveillance frequency should be based on the severity of FGR and UA abnormalities. Progressive deterioration of UA Doppler velocimetry warrants more intensive monitoring every 2–3 days when absent or reversed UA-EDF is present. There is no consensus on monitoring frequency, however, suggested management strategies have been described elsewhere<sup>29,42,67</sup>.

MCA Doppler is one of the first parameters that becomes abnormal in early FGR. There seems to be a weak association between low MCA-PI and adverse short-term neonatal outcome and between low MCA-PI and high UCR and 2-year adverse neurodevelopmental outcome<sup>52</sup>. However, gestational age at delivery and birth weight have the most pronounced impact on these outcomes<sup>52</sup>. Thus, MCA Doppler seems to guide monitoring before 32 weeks of gestation but there is no evidence that it should be used to determine delivery timing.

Around 70% of women with early FGR will develop hypertensive disorders of pregnancy, mainly pre-eclampsia<sup>68</sup>. Thus, regular blood-pressure assessment, and monitoring of urinary protein/creatinine ratio and baseline renal–hepatic function in asymptomatic women with early FGR are recommended. Although maternal PlGF testing might be useful<sup>69</sup>, the value of biomarkers in the diagnosis and management of FGR in the absence of maternal hypertension remains undefined.

#### *Corticosteroid prophylaxis*

All available guidelines on early FGR recommend corticosteroid prophylaxis to prevent neonatal respiratory distress syndrome if the birth is likely to occur before 34 + 0 weeks<sup>43,67,70–74</sup>. However, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends corticosteroid prophylaxis up to 35 + 6 weeks<sup>67</sup>. Despite this recommendation, it is worth noting that no randomized trial has been performed in order to establish whether the benefits of corticosteroids in premature fetuses also apply to premature growth-restricted fetuses, in whom the reduced metabolism of corticosteroids by a smaller placenta and the already high level of endogenous adrenal corticosteroids might further damage the white matter of the brain and myelination<sup>75</sup>. In fetuses with absent or reversed UA-EDF, enhanced daily surveillance is warranted during steroid administration<sup>76</sup>.

#### *Magnesium sulfate prophylaxis*

There is good evidence for the efficacy of magnesium sulfate for fetal neuroprotection in the context of preterm delivery, however, the exact gestational-age threshold at which this attenuates remains unclear<sup>77</sup>. Many guidelines and studies recommend magnesium sulfate prophylaxis for neuroprotection in growth-restricted fetuses, though the suggested time of commencement varies, being < 32–33 weeks<sup>73</sup>, < 32 weeks<sup>70,72</sup>, < 30 weeks<sup>78</sup> or < 29 weeks' gestation<sup>79</sup>. In the absence of strong evidence regarding the optimum gestational age of magnesium sulfate prophylaxis that would allow for uniform application among countries, we recommend to refer to local or national guidelines.


#### *When and how to deliver*

A large prospective international multicenter study provided evidence that early gestational age at delivery and low birth weight are the primary quantifying parameters that adversely impact on the neonatal outcome of fetuses with early-onset FGR<sup>55</sup>. Indeed, for extreme prematurity (< 27 weeks) and extremely low birth weight (< 600 g), each day of prolongation of the pregnancy improves neonatal survival by 2%. After 27 weeks, ductus venosus Doppler parameters emerged as the primary predictor of neonatal outcome<sup>55</sup>.

The first randomized controlled trial on timing of delivery in FGR was the Growth Restriction Intervention Trial (GRIT)<sup>80,81</sup>. The study evaluated the effect of immediate delivery *vs* expectant management when the clinicians were uncertain about the optimal timing of delivery of a compromised fetus. The median time to delivery was 4.9 days in the expectant-management group compared with 0.9 days in the immediate-delivery arm, and there was no significant difference in neurodevelopmental outcome at 2 years or at school age between the two groups<sup>82</sup>.

The TRUFFLE study is the largest randomized trial on timing of delivery in early FGR and was based on three randomization arms: early ductus venosus Doppler changes (PI > 95<sup>th</sup> percentile), late ductus venosus Doppler changes (a-wave at or below baseline) and reduced fetal heart rate STV on cCTG (< 3.5 ms before 29 weeks and < 4.0 ms thereafter)<sup>83</sup>. In addition, in all three arms, safety-net criteria were applied as an absolute indication for delivery, and were represented by spontaneous repeated persistent unprovoked fetal heart rate decelerations in all three arms or by STV < 2.6 ms at 26 + 0 to 28 + 6 weeks and < 3.0 ms at 29 + 0 to 31 + 6 weeks in the ductus venosus arms. The protocol recommended delivery if reversed UA-EDF occurred after 30 weeks or if there was absent UA-EDF after 32 weeks. Overall, the TRUFFLE study provided evidence that timing of delivery based on ductus venosus Doppler measurement in conjunction with cCTG safety-net criteria improves long-term (2-year) neurodevelopmental outcome in surviving infants. The cCTG STV 'safety net' was deliberately set at a level below that of the two ductus venosus randomized groups. Figure 1 presents the protocol recommended by the TRUFFLE study for monitoring and managing pregnancies with early FGR<sup>66</sup>. Despite the fact that data from the TRUFFLE study showed better-than-expected results in terms of infant survival without neurological impairment (82% of children), the gestational age at study entry and at delivery and birth weight were strongly related to adverse outcome. It is important to highlight that outcomes similar to that of the TRUFFLE trial can be replicated only by using the monitoring strategy and delivery-decision criteria based on ductus venosus Doppler and cCTG in conjunction.

If cCTG is not available or not used, delivery timing should be based on combination of Doppler velocimetry indices (mainly ductus venosus before 30 weeks) and conventional CTG, or BPP where this is undertaken. The



**Figure 1** Flowchart explaining protocol recommended by TRUFFLE study for monitoring and management of pregnancies with early diagnosis of fetal growth restriction (FGR). AC, abdominal circumference; cCTG, computerized cardiotocography; DV, ductus venosus; EDF, end-diastolic flow; PI, pulsatility index; STV, short-term variation. Reproduced from Bilardo *et al.*<sup>66</sup>.

presence of repeated spontaneous unprovoked decelerations is an indication for delivery. However, when visually interpreting the fetal heart reactivity on conventional CTG, the gestational age and corresponding fetal maturity should be taken into account. Similarly, an absolute indication for delivery is maternal condition (e.g. severe pre-eclampsia, eclampsia, HELLP syndrome) or obstetric emergency conditions, such as placental abruption.

Considering the strong association with severe placental insufficiency and fetal hypoxemia/hypoxia, planned Cesarean section is indicated in the majority of early-onset cases of FGR. Importantly, delivery is indicated based on maternal indications, mainly hypertensive disorders of pregnancy, that could adversely impact the perinatal and maternal outcome<sup>68</sup>.

### Recommendations

- Pregnancies with early FGR should be monitored and managed in tertiary-level units with the highest level neonatal care (**GOOD PRACTICE POINT**).
- Multidisciplinary management by neonatology and maternal–fetal medicine specialists is indicated (**GOOD PRACTICE POINT**).
- Multimodality assessment, including CTG and UA, MCA and ductus venosus Doppler evaluation, is recommended (**GRADE OF RECOMMENDATION: A**).
- When cCTG is available, STV should be the main parameter assessed (**GRADE OF RECOMMENDATION: A**).
- Monitoring should be scheduled based on the severity of FGR and alterations in UA Doppler (**GOOD PRACTICE POINT**).
- Delivery should be based on biophysical assessments or maternal indication, as follows:
  - At any gestational age: presence of maternal indication (e.g. severe pre-eclampsia, HELLP syndrome) or obstetric emergency requiring delivery (**GOOD PRACTICE POINT**);
  - 24 + 0 to 25 + 6 weeks: personalized management (**GOOD PRACTICE POINT**);
  - ≥ 26 + 0 weeks, deliver if any of the following is present:
    - Spontaneous repeated persistent unprovoked fetal heart rate decelerations (**GRADE OF RECOMMENDATION: A**);
    - Altered BPP (score ≤ 4) (**GOOD PRACTICE POINT**);
  - 26 + 0 to 28 + 6 weeks: deliver if ductus venosus a-wave is at or below baseline or STV < 2.6 ms (**GRADE OF RECOMMENDATION: A**);
  - 29 + 0 to 31 + 6 weeks: deliver if ductus venosus a-wave is at or below baseline or STV < 3.0 ms (**GRADE OF RECOMMENDATION: A**);
  - 32 + 0 to 33 + 6 weeks (permitted after 30 + 0 weeks): deliver if UA-EDF is reversed or STV < 3.5 ms (**GOOD PRACTICE POINT**);
  - ≥ 34 + 0 weeks (permitted after 32 + 0 weeks): deliver if UA-EDF is absent or STV < 4.5 ms (**GOOD PRACTICE POINT**).
- Corticosteroid prophylaxis is recommended if delivery is planned before 34 + 0 weeks of gestation (**GRADE OF RECOMMENDATION: B**).

- Elective Cesarean delivery is recommended if one or more of the following is present: abnormal cCTG STV, ductus venosus Doppler alteration, absent or reversed UA-EDF, altered BPP, maternal indication (GOOD PRACTICE POINT).

### Late-onset fetal growth restriction

The pathophysiology of late FGR differs from that of early FGR. Late FGR is characterized by milder and more aspecific placental lesions and/or alteration in oxygen and nutrient diffusion<sup>84,85</sup>. Consequently, alterations in UA Doppler and venous districts are rare and fail to identify the vast majority of late-FGR cases or to predict adverse outcome in these fetuses<sup>40</sup>. Several studies have found an association between MCA vasodilatation (i.e. reduction in MCA-PI) or the alteration of its ratio with UA-PI and poorer perinatal outcome<sup>86</sup>, including stillbirth<sup>39</sup>, higher risk of Cesarean delivery<sup>87–89</sup>, and increased risk of abnormal neurodevelopment at birth<sup>90</sup> and at 2 years of age<sup>91</sup>. The rationale for using the ratios of MCA-PI and UA-PI (CPR and UCR) is that they can identify subtle changes between placental and cerebral blood-flow perfusion that may not be appreciated by evaluation of a single parameter. Furthermore, it has been suggested that evaluation of the CPR may improve the prediction of adverse perinatal outcome in growth-restricted fetuses<sup>92–94</sup>.

The biophysical abnormalities that characterize late FGR include alteration of fetal breathing, decreased amniotic fluid volume and loss of fetal heart rate reactivity on conventional CTG. However, in fetuses with late FGR, it seems that BPP becomes abnormal only shortly before stillbirth, and therefore, it is not useful in the determination of monitoring intervals<sup>39</sup>.

Despite presenting with milder clinical form than early FGR, late FGR is still associated with poor perinatal outcome<sup>87,95</sup> and longer-term educational attainment<sup>91,96,97</sup>. In the TRUFFLE study, the risk of poor neurodevelopmental outcome in babies that were delivered after 32 weeks' gestation remained static until term<sup>98</sup>. This may be due to several factors. The pathophysiology of late FGR is still not completely understood and this may determine a lower identification rate of fetuses exposed to growth restriction near term<sup>99</sup>. Moreover, fetuses near term seem to have reduced tolerance to hypoxemia<sup>100</sup>, possibly because of their relatively high metabolic rate, compared with fetuses at an earlier gestation. Thus, frequent monitoring of pregnancies with late FGR is warranted in the same way as for those with early FGR.

### How to monitor

At present, MCA-PI and its ratios to UA-PI are the most important Doppler parameters in the surveillance of late FGR. In the presence of UA-PI > 95<sup>th</sup> percentile, monitoring at least once or twice a week is indicated. A large retrospective study showed that, in FGR pregnancies

after 34 + 0 weeks of gestation, the median interval between a low MCA-PI and stillbirth was ≤ 5 days, suggesting that, if delivery has not been indicated by that time, twice-weekly Doppler surveillance may be required after 34 weeks<sup>39</sup>. Moreover, in the same study, almost 90% of stillbirths occurred within 1 week of a normal BPP score in the presence of cerebral vasodilatation, suggesting that BPP may have poor value in determining the frequency of fetal monitoring<sup>39</sup>.

Considering the fact that some concerns have been raised regarding the interobserver reliability of MCA-PI measurement, when alteration in MCA-PI, CPR or UCR is encountered, the measurement should be confirmed within 24 h to avoid false-positive results, especially when timing of delivery is based on this finding<sup>101</sup>.

### Corticosteroid prophylaxis

There is a lack of consensus between guidelines with respect to corticosteroid prophylaxis between 34 and 36 weeks' gestation. Most guidelines on FGR recommend corticosteroid prophylaxis if the birth is likely to occur before 34 + 0 weeks<sup>70–74</sup>, however, the RCOG recommends corticosteroid prophylaxis up to 35 + 6 weeks<sup>67</sup>.

### When and how to deliver

There is no international consensus on the timing of delivery in late FGR, due to the lack of interventional management randomized trials based on Doppler indices in these pregnancies. In fact, national guidelines for the management of FGR are highly variable<sup>43</sup>.

The only randomized interventional trial on FGR at or close to term is the Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT) study<sup>102</sup>. The study compared the effect of induction of labor *vs* expectant monitoring in singleton pregnancies beyond 36 + 0 weeks of gestation with suspected FGR. The study did not take into account any Doppler assessment and the only Doppler parameter reported was absent EDF in the UA (present in 14/650 pregnancies). The induction-of-labor policy, compared with expectant management, did not affect the rate of adverse neonatal outcome or neurodevelopmental and behavioral outcome at 2 years of age, except for in children with birth weight below the 2.3<sup>rd</sup> percentile<sup>103</sup>. Moreover, it did not affect the rates of instrumental vaginal delivery and Cesarean section. In the induction-of-labor group, more neonates were admitted to intermediate-level care, but this outcome was reduced when considering only induction after 38 weeks of gestation<sup>104</sup>. Importantly, the proportion of neonates with birth weight below the 3<sup>rd</sup> percentile was greater in the expectant-monitoring arm, as was the proportion of women who developed pre-eclampsia. Based on these findings, it would appear that induction of labor for suspected FGR after 38 weeks' gestation is not associated with increased incidence of instrumental vaginal delivery or Cesarean section, or



adverse neonatal or 2-year child outcome, while it seems to be associated with decreased incidence of neonates with extremely low birth weight and of progression to pre-eclampsia. Of note, fetuses at term with birth weight below the 3<sup>rd</sup> percentile have the highest risk of stillbirth, approximately 1:100<sup>12</sup>, hence these pregnancies should not exceed 37 + 6 weeks of gestation, independent of Doppler findings. All cases of stillbirth in the DIGITAT trial occurred among women who, despite meeting the inclusion criteria, declined to participate (approximately 1%, pers. comm.). This stresses the importance of monitoring growth-restricted fetuses at or near term, and timely delivery.

In pregnancies with late FGR and UA-PI above the 95<sup>th</sup> percentile, expert opinion is that delivery should be considered when the gestation is beyond 36 + 0 weeks and not later than 37 + 6 weeks<sup>105</sup>.

Though **cerebral redistribution** is associated with adverse short- and long-term perinatal outcome<sup>49,106–108</sup>, there is **currently no evidence as to how cerebral Doppler should be utilized in the delivery timing of FGR**. However, it seems reasonable that, in pregnancies with late FGR and signs of cerebral blood-flow redistribution, delivery should be considered at around 38 + 0 weeks and not later than 38 + 6 weeks. It is important that each unit predisposes and follows a precise dedicated monitoring protocol, based also on local experience and resources.


Depending on the clinical situation (parity, EFW, cervical findings), induction of labor may be undertaken, but this is not recommended in the context of critical UA Doppler findings (i.e. absent or reversed EDF)<sup>43,105</sup>. Continuous fetal heart rate monitoring during labor should be undertaken. Figure 2 summarizes the proposed management of FGR pregnancies based on cCTG and Doppler findings.

## Recommendations

- In pregnancies with late FGR, delivery should be based on biophysical assessments or maternal indication as follows:
  - At any gestational age, deliver if one of the following is present:
    - Spontaneous repeated persistent unprovoked fetal heart rate decelerations (**GOOD PRACTICE POINT**);
    - Altered BPP (score  $\leq 4$ ) (**GOOD PRACTICE POINT**);
    - Maternal indication (e.g. severe pre-eclampsia, HELLP syndrome) or obstetric emergency requiring delivery (**GOOD PRACTICE POINT**);
    - cCTG STV  $< 3.5$  ms at 32 + 0 to 33 + 6 weeks and  $< 4.5$  ms at  $\geq 34$  + 0 weeks (**GOOD PRACTICE POINT**);
    - Absent or reversed UA-EDF (**GOOD PRACTICE POINT**);
  - 36 + 0 to 37 + 6 weeks: deliver if UA-PI  $> 95^{\text{th}}$  percentile or AC/EFW  $< 3^{\text{rd}}$  percentile (**GOOD PRACTICE POINT**);
  - 38 + 0 to 39 + 0 weeks: deliver if there is evidence of cerebral blood-flow redistribution or any other feature of FGR (**GOOD PRACTICE POINT**).
- In the absence of contraindications, induction of labor is indicated (**GOOD PRACTICE POINT**).
- During labor, continuous fetal heart rate monitoring is recommended (**GOOD PRACTICE POINT**).

## Small-for-gestational age

SGA is often considered as a constitutionally small fetus that is otherwise healthy; it is frequently the case that



**Figure 2** Recommended management of pregnancies with fetal growth restriction (FGR), based on computerized cardiotocography and Doppler findings. \*Permitted after 30 + 0 weeks. †Permitted after 32 + 0 weeks. AC, fetal abdominal circumference; AEDF, absent end-diastolic flow; DV, ductus venosus; EFW, estimated fetal weight; PI, pulsatility index; REDF, reversed end-diastolic flow; STV, short-term variation; UA, umbilical artery; wks, gestational weeks.

the SGA categorization is applied to a small baby that is structurally normal and has normal Doppler findings. In these cases, the adoption of customized growth charts has been suggested to reduce the proportion of SGA<sup>109</sup>. However, there is evidence suggesting that SGA with normal fetoplacental Doppler can be associated with accelerated placental aging<sup>110</sup>, signs of placental underperfusion<sup>111</sup>, lower umbilical vein blood flow volume<sup>112</sup>, altered maternal hemodynamics<sup>113</sup> and greater incidence of Cesarean section for fetal distress<sup>87</sup> compared with AGA fetuses. Such evidence poses the question as to whether there might be a subgroup of SGA fetuses that do in fact suffer from 'stunted' fetal growth, which adapt to a poor nutritional environment and are not identified by standard biophysical diagnostic tools. Further research is needed to better understand this hypothesis.

#### *How to monitor*

At the diagnosis of SGA, fetal Doppler indices (UA-PI, MCA-PI and their ratios) and uterine artery Doppler should be evaluated.

In the case of late SGA (after 32 weeks), once uterine artery Doppler has been assessed at diagnosis, there is no need for uterine artery Doppler to be re-evaluated at each visit as, usually, it remains unchanged from diagnosis of SGA to delivery<sup>114</sup>. Fortnightly assessment of fetal growth is recommended<sup>115</sup>. Late-SGA fetuses with abnormal uterine artery PI at diagnosis, compared to those without, are more likely to progress to brain sparing, in other words 'cross over' to FGR, and this usually occurs at earlier gestational-age epochs. Even late-SGA fetuses with normal uterine artery PI can progress to brain sparing, albeit less frequently and 1–2 weeks later than fetuses with abnormal uterine artery PI<sup>114</sup>.

#### *When and how to deliver*

Reports suggest that universal induction of labor at term may be more beneficial than expectant management in terms of reduced perinatal mortality<sup>116,117</sup>, without increasing the rate of Cesarean section or operative vaginal delivery<sup>118–120</sup>. This is true for both nulliparous women aged  $\geq 35$  years<sup>116,118</sup> and unselected populations<sup>117,119,120</sup>.

Considering that the major cause of perinatal death at term is stillbirth and that some SGA fetuses might suffer some degree of stunted growth that is not adequately identified by current biophysical tools, it is reasonable to consider delivery after 38 + 0 weeks of gestation, and the pregnancy should not exceed 39 + 0 weeks, in order to reduce the risk of severe growth restriction or stillbirth in fetuses identified as SGA. This recommendation is also supported by the findings of the DIGITAT study<sup>102,104</sup>. Induction of labor is appropriate depending on the clinical situation, and continuous fetal heart rate monitoring in labor should be performed in these cases.

#### *Recommendations*

- Fetal Doppler velocimetry should be performed both at the diagnosis of SGA and during follow-up (**GOOD PRACTICE POINT**).
- In case of late SGA, fortnightly assessment of fetal growth and weekly assessment of UA-PI, MCA-PI, CPR and UCR is recommended (**GOOD PRACTICE POINT**).
- When SGA has been identified, delivery should be planned from 38 + 0 weeks and the pregnancy should not exceed 39 + 0 weeks of gestation (**GRADE OF RECOMMENDATION: A**).
- Continuous fetal heart rate monitoring during labor is indicated (**GOOD PRACTICE POINT**).

#### **What is not known and implications for research**

The Delphi consensus on the criteria for FGR diagnosis<sup>16</sup> is of importance as it has established a uniform definition of early and late FGR. However, it is still not clear whether a proportion of fetuses with AC or EFW below the 10<sup>th</sup> percentile (namely SGA) with normal umbilical and cerebral Doppler indices might suffer from stunted fetal growth as suggested by recent findings<sup>110,121</sup>. This question warrants further exploration. It is hypothesized that even before the signs of hypoxemia establish, there is a 'preclinical' phase during which the fetus is exposed to a reduced supply of nutrients and oxygen to which it responds by reduced growth and oxidative metabolism. There are several hypotheses regarding the underlying pathophysiological processes of fetal growth impairment, such as inadequate maternal perfusion of the uterus due to overrun of the maternal hemodynamic adaptation potential, overrun of the placental potential in response to increasing fetal needs, or placental senescence due to oxidative stress. It may be that UA Doppler alterations and signs of cerebral blood-flow redistribution are not sophisticated enough to capture and discriminate these imbalances between fetal needs and maternal and/or placental potential before hypoxemia establishes. In this respect, more efforts should be made to identify potential predictors of the subgroup of SGA fetuses that is at increased risk of perinatal and long-term adverse outcomes. New emerging biophysical and biochemical tools, such as alternative analysis of fetal heart rate acceleration and deceleration parameters<sup>122</sup>, evaluation of maternal hemodynamics<sup>113</sup>, evaluation of umbilical vein blood-flow volume<sup>85,112,123</sup> and even assessment of uterine blood-flow volume<sup>124,125</sup> could help to disentangle the different aspects of SGA and FGR.

The finding that sFlt-1/PlGF ratio can predict the short-term presence or absence of pre-eclampsia<sup>33</sup> opens the possibility that placental protein markers can offer considerably enhanced screening test precision to distinguish the healthy SGA fetus from the fetus with placenta-mediated FGR that is at risk of stillbirth and asphyxia-related morbidity. In women with hypertensive disorders, the sFlt-1/PlGF ratio has been shown to be able to differentiate cases with pre-eclampsia and SGA from

those with pre-eclampsia and AGA fetuses<sup>126</sup>, and this should be explored further in pregnant patients monitored for SGA and/or FGR<sup>34</sup>.

Early FGR is associated with complications related to prematurity, as preterm birth is often necessitated to prevent stillbirth. There is a strong desire to delay progression of the condition once the diagnosis is made. Attempts have been made by several research groups (STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset intrauterine growth Restriction) consortium) to evaluate the role of sildenafil, a phosphodiesterase Type-5 inhibitor, in improving the outcome of fetuses with early FGR. It is believed that its potential vasodilatory effect on the uterine vessels might improve fetal growth *in utero*. The UK-based randomized placebo-controlled trial demonstrated that administration of sildenafil at a dose of 25 mg three times daily ( $n = 70$ ) *vs* placebo ( $n = 65$ ) does not prolong the pregnancy or improve outcomes in severe early-onset FGR diagnosed between 22 + 0 and 29 + 6 weeks of gestation<sup>127</sup>. A similar trial from New Zealand and Australia, including 122 cases of early FGR, demonstrated that maternal use of sildenafil has no effect on fetal growth velocity<sup>128</sup>. Significant concerns regarding the safety of sildenafil during pregnancy were raised following an excess of neonatal deaths due to pulmonary hypertension in one trial based in The Netherlands, and it is currently recommended that sildenafil should not be used in FGR outside the setting of high-quality randomized clinical trials<sup>129</sup>.

Several novel approaches are being investigated for improving the outcome of pregnancies with early-onset FGR. The EVERREST (doEs Vascular endothelial growth factor gene therapy safEly impRove outcome in seveRe Early-onset fetal growth reSTriction?) group<sup>125</sup> is planning an uncontrolled open-label trial in pregnancies affected by early FGR in order to evaluate the efficacy of localized injected maternal vascular endothelial growth factor gene therapy to improve fetal growth. Given that high maternal vascular resistance and low cardiac output are characteristic in early FGR, vasodilator agents and increasing intravascular volume have been suggested to improve fetal growth and prolong gestation<sup>130</sup>. Importantly, therapies for maternal hypertension that reduce cardiac output, such as beta blockers, have been linked to poor perinatal outcome and stillbirth and should be used with caution in these cases.

Besides the need for homogeneous application of Doppler indices, thresholds and reference ranges, the question regarding their clinical utility for monitoring of and timing delivery in FGR pregnancies diagnosed > 32 weeks' gestation is still to be answered. The evidence of association between signs of cerebral blood-flow redistribution and adverse pregnancy outcome is based mainly on retrospective and observational studies, in which the application of Doppler indices might have influenced pregnancy management and outcome, and therefore introduced bias. Currently, there is no randomized interventional trial on the utility of Doppler parameters in timing delivery in late FGR. Thus, the key research

question is whether early delivery of fetuses with late FGR and signs of cerebral blood-flow redistribution is beneficial (by removing the fetus from exposure to a hostile environment and hypoxemia) or harmful (by inducing late prematurity). A study of this kind should address the issues of perinatal morbidity and mortality, as well as long-term neurodevelopmental outcomes. Moreover, it is not clear which monitoring policy is most beneficial and which Doppler parameters and thresholds perform best in late FGR. Ongoing randomized controlled trials on this topic will provide answers to these important questions.

## CONCLUSION

Early diagnosis, close follow-up and timely delivery of pregnancies with FGR are of crucial importance for perinatal short- and long-term outcome. The identification of FGR is not always straightforward, for several reasons. First, a single biometric measurement of fetal size is not sufficient to evaluate fetal growth, except perhaps in the case of extremely small fetal size. Thus, additional biophysical tools and/or evaluations are needed in order to identify FGR. Second, there are two phenotypes of FGR that differ significantly in many aspects. Knowledge of the clinical manifestation and progress of early-onset and late-onset FGR is of crucial importance for all aspects of management (from diagnosis to delivery). At present, the most recognized criteria to define early and late FGR are those derived from an international Delphi survey consensus<sup>16</sup>.

Once the diagnosis of FGR has been made, multimodality assessment (including Doppler velocimetry, cCTG and BPP), which may differ between countries, is recommended. Early FGR is associated more strongly with abnormal trophoblastic invasion and consequent placental insufficiency. The risk of perinatal mortality and morbidity and long-term adverse outcome is very high in these pregnancies, and depends both on the severity of growth restriction and prematurity. For this reason, pregnancies with early FGR should be managed in multidisciplinary tertiary-level units. Despite the severity of early FGR, the cascade of Doppler alterations is quite well-known and randomized controlled trials have provided a robust level of evidence for delivery criteria.

Late FGR has a milder clinical presentation than does early FGR, and hence, it is not associated with severe prematurity but can still be associated with significant morbidity. Despite that, at present, the diagnosis and management of late FGR, especially near term, is complex. The assessment of MCA-PI and its ratios to UA-PI have a central role in the identification of late FGR. However, there is no clear evidence as to whether the decision to deliver based on Doppler evaluation of cerebral blood-flow redistribution might be beneficial in terms of short- and long-term neurodevelopmental outcome and which is the optimal gestational age at which to deliver these pregnancies.

In conclusion, the diagnosis and management of FGR pregnancies still pose some concerns and dilemmas. In



fact, there is some evidence that even SGA fetuses with normal Doppler velocimetry might suffer some degree of growth restriction not identifiable by standard biophysical tools. New technologies and tools might be helpful in differentiating between SGA and FGR, and randomized controlled trials on management that are in progress will hopefully provide clear evidence on some unanswered questions. The real challenge remains to determine whether therapeutic intervention in FGR will ever be feasible.

## GUIDELINE AUTHORS

This Guideline was produced on behalf of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) by the following authors, and peer reviewed by the Clinical Standards Committee.

**C. C. Lees**, Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, London, UK; and Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; and Department of Development & Regeneration, KU Leuven, Leuven, Belgium

**T. Stampalija**, Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; and Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy

**A. A. Baschat**, Johns Hopkins Center for Fetal Therapy, Departments of Gynecology & Obstetrics and Pediatric Surgery, Johns Hopkins University, Baltimore, MD, USA

**F. da Silva Costa**, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; and Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Victoria, Australia

**E. Ferrazzi**, Department of Woman, Child and Neonate, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

**F. Figueras**, Fetal Medicine Research Center, BCNatal Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Institut Clínic de Ginecologia, Obstetricia i Neonatologia, University of Barcelona, Barcelona, Spain

**K. Hecher**, Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

**J. Kingdom**, Placenta Program, Maternal-Fetal Medicine Division, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

**L. C. Poon**, Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong SAR

**L. J. Salomon**, Obstétrique et Plateforme LUMIERE, Hôpital Necker-Enfants Malades (AP-HP) et Université de Paris, Paris, France

**J. Unterscheider**, Department of Maternal Fetal Medicine, Royal Women's Hospital, Melbourne, Victoria, Australia; and Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia.

## CITATION

This Guideline should be cited as: 'Lees CC, Stampalija T, Baschat AA, da Silva Costa F, Ferrazzi E, Figueras F, Hecher K, Kingdom J, Poon LC, Salomon LJ, Unterscheider J. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. *Ultrasound Obstet Gynecol* 2020; 56: 298–312.'

## REFERENCES

1. Miller SL, Huppi PS, Mallard C. The consequences of fetal growth restriction on brain structure and neurodevelopmental outcome. *J Physiol* 2016; 594: 807–823.
2. Francis JH, Permezel M, Davey MA. Perinatal mortality by birthweight centile. *Aust N Z J Obstet Gynecol* 2014; 54: 354–359.
3. Barker DJ, Osmond C, Forsén TJ, Kajantie E, Eriksson JG. Trajectories of growth among children who have coronary events as adults. *N Engl J Med* 2005; 353: 1802–1809.
4. Flenady V, Wojcieszek AM, Middleton P, Ellwood D, Erwich JJ, Coory M, Khong TY, Silver RM, Smith GC, Boyle FM, Lawn JE, Blencowe H, Leisher SH, Gross MM, Horey D, Farrales L, Bloomfield F, McCowan L, Brown SJ, Joseph KS, Zeitlin J, Reinebrant HE, Ravaldi C, Vannacci A, Cassidy J, Cassidy P, Farquhar C, Wallace E, Siassakos D, Heazell AE, Storey C, Sadler L, Petersen S, Frøen JF, Goldenberg RL, Lancet Ending Preventable Stillbirths study group; Lancet Stillbirths In High-Income Countries Investigator Group. Stillbirths: recall to action in high-income countries. *Lancet* 2016; 387: 691–702.
5. Nohuz E, Rivière O, Coste K, Vendittelli F. Prenatal identification of small-for-gestational-age and risk of neonatal morbidity and stillbirth. *Ultrasound Obstet Gynecol* 2020; 55: 621–628.
6. Salomon LJ, Alfirevic Z, Da Silva Costa F, Deter RL, Figueras F, Ghi T, Glanc P, Khalil A, Lee W, Napolitano R, Papageorgiou A, Sotiriadis A, Stirrman J, Toi A, Yeo G. ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth. *Ultrasound Obstet Gynecol* 2019; 53: 715–723.
7. Poon LC, Tan MY, Yerlikaya G, Syngelaki A, Nicolaides KH. Birth weight in live births and stillbirths. *Ultrasound Obstet Gynecol* 2016; 48: 602–606.
8. Bligh LN, Flatley CJ, Kumar S. Reduced growth velocity at term is associated with adverse neonatal outcomes in non-small for gestational age infants. *Eur J Obstet Gynecol Reprod Biol* 2019; 240: 125–129.
9. Morales-Roselló J, Khalil A, Morlando M, Papageorgiou A, Bhide A, Thilaganathan B. Changes in fetal Doppler indices as a marker of failure to reach growth potential at term. *Ultrasound Obstet Gynecol* 2014; 43: 303–310.
10. Prior T, Paramasivam G, Bennett P, Kumar S. Are fetuses that fail to achieve their growth potential at increased risk of intrapartum compromise? *Ultrasound Obstet Gynecol* 2015; 46: 460–464.
11. Sovio U, White IR, Dacey A, Pasupathy D, Smith GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. *Lancet* 2015; 386: 2089–2097.
12. Moraitis AA, Wood AM, Fleming M, Smith GC. Birth weight percentile and the risk of term perinatal death. *Obstet Gynecol* 2014; 124: 274–283.
13. Vasak B, Koenen SV, Koster MP, Hukkelhoven CW, Franx A, Hanson MA, Visser GH. Human fetal growth is constrained below optimal for perinatal survival. *Ultrasound Obstet Gynecol* 2015; 45: 162–167.
14. McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. *N Engl J Med* 1999; 340: 1234–1238.
15. Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. *BMJ* 2013; 346: f108.
16. Gordijn SJ, Beune IM, Thilaganathan B, Papageorgiou A, Baschat AA, Baker PN, Silver RM, Wynia K, Ganzevoort W. Consensus definition of fetal growth restriction: a Delphi procedure. *Ultrasound Obstet Gynecol* 2016; 48: 333–339.
17. Iliodromiti S, Mackay DF, Smith GC, Pell JP, Sattar N, Lawlor DA, Nelson SM. Customised and Noncustomised Birth Weight Centiles and Prediction of Stillbirth and Infant Mortality and Morbidity: A Cohort Study of 979,912 Term Singleton Pregnancies in Scotland. *PLoS Med* 2017; 14: e1002228.
18. Royston P, Altman DG. Design and analysis of longitudinal studies of fetal size. *Ultrasound Obstet Gynecol* 1995; 6: 307–312.
19. Deter RL, Lee W, Yeo L, Erez O, Ramamurthy U, Naik M, Romero R. Individualized growth assessment: conceptual framework and practical implementation for the evaluation of fetal growth and neonatal growth outcome. *Am J Obstet Gynecol* 2018; 218: S656–678.
20. MacDonald TM, Hui L, Tong S, Robinson AJ, Dane KM, Middleton AL, Walker SP. Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: a prospective cohort study. *BMC Med* 2017; 15: 164.



21. Levitska K, Higgins M, Keating S, Melamed N, Walker M, Sebire NJ, Kingdom JC. Placental Pathology in Relation to Uterine Artery Doppler Findings in Pregnancies with Severe Intrauterine Growth Restriction and Abnormal Umbilical Artery Doppler Changes. *Am J Perinatol* 2017; 34: 451–457.
22. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. *Placenta* 2009; 30: 473–482.
23. Richardson BS, Bocking AD. Metabolic and circulatory adaptations to chronic hypoxia in the fetus. *Comp Biochem Physiol A Mol Integr Physiol* 1998; 119: 717–723.
24. Kiserud T, Kessler J, Ebbing C, Rasmussen S. Ductus venosus shunting in growth-restricted fetuses and the effect of umbilical circulatory compromise. *Ultrasound Obstet Gynecol* 2006; 28: 143–149.
25. Ferrazzi E, Lees C, Acharya G. The controversial role of the ductus venosus in hypoxic human fetuses. *Acta Obstet Gynecol Scand* 2019; 98: 823–829.
26. Manning FA, Snijders R, Harman CR, Nicolaides K, Menticoglou S, Morrison I. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. *Am J Obstet Gynecol* 1993; 169: 755–763.
27. Turan S, Turan OM, Berg C, Moyano D, Bhide A, Bower S, Thilaganathan B, Gembruch U, Nicolaides K, Harman C, Baschat AA. Computerized fetal heart rate analysis, Doppler ultrasound and biophysical profile score in the prediction of acid-base status of growth-restricted fetuses. *Ultrasound Obstet Gynecol* 2007; 30: 750–756.
28. Nageotte MP, Towers CV, Asrat T, Freeman RK. Perinatal outcome with the modified biophysical profile. *Am J Obstet Gynecol* 1994; 170: 1672–1676.
29. Baschat AA. Planning management and delivery of the growth-restricted fetus. *Best Pract Res Clin Obstet Gynaecol* 2018; 49: 53–65.
30. Whigham CA, MacDonald TM, Walker SP, Hannan NJ, Tong S, Kaitu'u-Lino TJ. The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development. *Placenta* 2019; 84: 28–31.
31. Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. *BMC Pregnancy Childbirth* 2015; 15: 191.
32. Proctor LK, Toal M, Keating S, Chitayat D, Okun N, Windrim RC, Smith GC, Kingdom JC. Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. *Ultrasound Obstet Gynecol* 2009; 34: 274–282.
33. Zeisler H, Lurba E, Chantraine F, Vatis M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verloren S. Predictive Value of the sFlt-1:PIGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med* 2016; 374: 13–22.
34. Gaccioli F, Sovio U, Cook E, Hund M, Charnock-Jones DS, Smith GCS. Screening for fetal growth restriction using ultrasound and the sFlt1/PIGF ratio in nulliparous women: a prospective cohort study. *Lancet Child Adolesc Health* 2018; 2: 569–581.
35. Griffin M, Seed PT, Webster L, Myers J, MacKillop L, Simpson N, Anumba D, Khalil A, Denbow M, Sau A, Hinshaw K, von Dadelszen P, Benton S, Girling J, Redman CW, Chappell LC, Shennan AH. Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. *Ultrasound Obstet Gynecol* 2015; 46: 182–190.
36. Kwiatkowski S, Bednarek-Jędrzejek M, Ksel J, Tousty P, Kwiatkowska E, Cymbaluk A, Rzepka R, Chudecka-Glaz A, Dolegowska B, Torbè A. sFlt-1/PIGF and Doppler ultrasound parameters in SGA pregnancies with confirmed neonatal birth weight below 10th percentile. *Pregnancy Hypertens* 2018; 14: 79–85.
37. Herraiz I, Quezada MS, Rodriguez-Calvo J, Gómez-Montes E, Villalain C, Galindo A. Longitudinal change of sFlt-1/PIGF ratio in singleton pregnancy with early-onset fetal growth restriction. *Ultrasound Obstet Gynecol* 2018; 52: 631–638.
38. Fabjan-Vodusek V, Kumer K, Osredkar J, Verdenik I, Gersak K, Premru-Srsen T. Correlation between uterine artery Doppler and the sFlt-1/PIGF ratio in different phenotypes of placental dysfunction. *Hypertens Pregnancy* 2019; 38: 32–40.
39. Crimmins S, Desai A, Block-Abraham D, Berg C, Gembruch U, Baschat AA. A comparison of Doppler and biophysical findings between liveborn and stillborn growth-restricted fetuses. *Am J Obstet Gynecol* 2014; 211: 669.e1–10.
40. Savchev S, Figueras F, Sanz-Cortes M, Cruz-Lemini M, Triunfo S, Botet F, Gratacos E. Evaluation of an optimal gestational age cut-off for the definition of early- and late-onset fetal growth restriction. *Fetal Diagn Ther* 2014; 36: 99–105.
41. Mifsud W, Sebire NJ. Placental pathology in early-onset and late-onset fetal growth restriction. *Fetal Diagn Ther* 2014; 36: 117–128.
42. Figueras F, Gratacos E. Stage-based approach to the management of fetal growth restriction. *Prenat Diagn* 2014; 34: 655–659.
43. McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. *Am J Obstet Gynecol* 2018; 218: S855–S868.
44. Molina LCG, Odibo L, Zientara S, Obican SG, Rodriguez A, Stout M, Odibo AO. Validation of Delphi procedure consensus criteria for defining fetal growth restriction. *Ultrasound Obstet Gynecol* 2020; 56: 61–66.
45. Bhide A, Acharya G, Bilardo CM, Brezinka C, Cafici D, Hernandez-Andrade E, Kalache K, Kingdom J, Kiserud T, Lee W, Lees C, Leung KY, Malinger G, Mari G, Prefumo F, Sepulveda W, Trudinger B. ISUOG practice guidelines: use of Doppler ultrasonography in obstetrics. *Ultrasound Obstet Gynecol* 2013; 41: 233–239.
46. Oros D, Ruiz-Martinez S, Staines-Urias E, Conde-Agudelo A, Villar J, Fabre E, Papageorgiou AT. Reference ranges for Doppler indices of umbilical and fetal middle cerebral arteries and cerebroplacental ratio: systematic review. *Ultrasound Obstet Gynecol* 2019; 53: 454–464.
47. Ruiz-Martinez S, Papageorgiou AT, Staines-Urias E, Villar J, Gonzalez De Agüero R, Oros D. Clinical impact of Doppler reference charts on management of small-for-gestational-age fetuses: need for standardization. *Ultrasound Obstet Gynecol* 2020; 56: 166–172.
48. Stampalija T, Ghi T, Rosolen V, Rizzo G, Ferrazzi EM, Prefumo F, Dall'Asta A, Quadrioglio M, Todros T, Frusca T; on behalf of SIEOG working group on fetal biometric charts. Current use and performance of the different fetal growth charts in the Italian population. *Eur J Obstet Gynecol Reprod Biol* 2020. DOI: 10.1016/j.ejogrb.2020.06.059.
49. Vollgraff Heidweiller-Schreurs CA, De Boer MA, Heymans MW, Schoonmade LJ, Bossuyt PMM, Mol BWJ, De Groot CJM, Bax CJ. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2018; 51: 313–322.
50. Hecher K, Spornol R, Stettner H, Szalay S. Potential for diagnosing imminent risk to appropriate- and small-for-gestational-age fetuses by Doppler sonographic examination of umbilical and cerebral arterial blood flow. *Ultrasound Obstet Gynecol* 1992; 2: 266–271.
51. Conde-Agudelo A, Villar J, Kennedy SH, Papageorgiou AT. Predictive accuracy of cerebroplacental ratio for adverse perinatal and neurodevelopmental outcomes in suspected fetal growth restriction: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2018; 52: 430–441.
52. Stampalija T, Arabin B, Wolf H, Bilardo CM, Lees C; TRUFFLE investigators. Is middle cerebral artery Doppler related to neonatal and 2-year infant outcome in early fetal growth restriction? *Am J Obstet Gynecol* 2017; 216: 521.e1–13.
53. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. *J Perinat Med* 2011; 39: 641–652.
54. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. *BJOG* 2006; 113: 580–589.
55. Baschat AA, Cosmi E, Bilardo CM, Wolf H, Berg C, Rigano S, Germer U, Moyano D, Turan S, Hartung J, Bhide A, Müller T, Bower S, Nicolaides KH, Thilaganathan B, Gembruch U, Ferrazzi E, Hecher K, Galan HL, Harman CR. Predictors of neonatal outcome in early-onset placental dysfunction. *Obstet Gynecol* 2007; 109: 253–261.
56. Ferrazzi E, Bozzo M, Rigano S, Bellotti M, Morabito A, Pardi G, Battaglia FC, Galan HL. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. *Ultrasound Obstet Gynecol* 2002; 19: 140–146.
57. Hecher K, Bilardo CM, Stigter RH, Ville Y, Hackelöer BJ, Kok HJ, Senat MV, Visser GH. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. *Ultrasound Obstet Gynecol* 2001; 18: 564–570.
58. Baschat AA, Kush M, Berg C, Gembruch U, Nicolaides KH, Harman CR, Turan OM. Hematologic profile of neonates with growth restriction is associated with rate and degree of prenatal Doppler deterioration. *Ultrasound Obstet Gynecol* 2013; 41: 66–72.
59. Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. *Ultrasound Obstet Gynecol* 2001; 18: 571–577.
60. Cosmi E, Ambrosini G, D'Antona D, Saccardi C, Mari G. Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses. *Obstet Gynecol* 2005; 106: 1240–1245.
61. Ting JY, Kingdom JC, Shah PS. Antenatal glucocorticoids, magnesium sulfate, and mode of birth in preterm fetal small for gestational age. *Am J Obstet Gynecol* 2018; 218: S818–S828.
62. Raju TNK, Mercer BM, Burchfield DJ, Joseph GF Jr. Periviable birth: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2014; 123: 1083–1096.
63. EXPRESS Group. Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden (EXPRESS). *Acta Paediatr* 2010; 99: 978–992.
64. Torrance HL, Bloemen MC, Mulder EJ, Nikkels PG, Derks JB, de Vries LS, Visser GH. Predictors of outcome at 2 years of age after early intrauterine growth restriction. *Ultrasound Obstet Gynecol* 2010; 36: 171–177.
65. Morsing E, Asard M, Ley D, Stjernqvist K, Marsál K. Cognitive function after intrauterine growth restriction and very preterm birth. *Pediatrics* 2011; 127: e874–882.
66. Bilardo CM, Hecher K, Visser GH, Papageorgiou AT, Marlow N, Thilaganathan B, Van Wassenae-Leemhuis A, Todros T, Marsal K, Frusca T, Arabin B, Brezinka C, Derks JB, Diemert A, Duvekot JJ, Ferrazzi E, Ganzevoort W, Martinelli P, Ostermayer E, Schlembach D, Valensise H, Thornton J, Wolf H, Lees C; TRUFFLE Group. Severe fetal growth restriction at 26–32 weeks: key messages from the TRUFFLE study. *Ultrasound Obstet Gynecol* 2017; 50: 285–290.
67. Royal College of Obstetricians and Gynecologists. Small-for-Gestational-Age Fetus, Investigation and Management (Green-top Guideline No. 31). 2013. [https://www.rcog.org.uk/globalassets/documents/guidelines/gtg\\_31.pdf](https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_31.pdf)
68. Lees C, Marlow N, Arabin B, Bilardo CM, Brezinka C, Derks JB, Duvekot J, Frusca T, Diemert A, Ferrazzi E, Ganzevoort W, Hecher K, Martinelli P, Ostermayer E, Papageorgiou AT, Schlembach D, Schneider KT, Thilaganathan B, Todros T, van Wassenae-Leemhuis A, Valcamonica A, Visser GH, Wolf H; TRUFFLE Group. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). *Ultrasound Obstet Gynecol* 2013; 42: 400–408.
69. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, Shennan AH, Chappell LC; PARROT trial group. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. *Lancet* 2019; 393: 1807–1818.
70. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics and the Society for Maternal-Fetal Medicine. ACOG Practice Bulletin No. 204: Fetal Growth Restriction. *Obstet Gynecol* 2019; 133: e97–109.

71. Lausman A, McCarthy FP, Walker M, Kingdom J. Screening, diagnosis, and management of intrauterine growth restriction. *J Obstet Gynaecol Can* 2012; **34**: 17–28.
72. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and Directorate of Clinical Strategy and Programmes, Health Service Executive. Guideline No 28. Fetal growth restriction - recognition, diagnosis & management. 2017. <https://www.hse.ie/eng/services/publications/clinical-strategy-and-programmes/fetal-growth-restriction.pdf>
73. Vayssi re C, Sentilhes L, Ego A, Bernard C, Cambourieu D, Flamant C, Gascoin G, Gaudineau A, Grang  G, Houfflin-Debarge V, Langer B, Malan V, Marcorelles P, Nizard J, Perrotin F, Salomon L, Senat MV, Serry A, Tessier V, Truffert P, Tsatsaris V, Arnaud C, Carbone B. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. *Eur J Obstet Gynecol Reprod Biol* 2015; **193**: 10–18.
74. New Zealand Maternal Fetal Medicine Network. Guideline for the management of suspected small for gestational age singleton pregnancies and infants after 34 weeks' gestation. New Zealand Maternal Fetal Medicine Network; 2014.
75. Magann EF, Haram K, Ounpraseuth S, Mortensen JH, Spencer HJ, Morrison JC. Use of antenatal corticosteroids in special circumstances: a comprehensive review. *Acta Obstet Gynecol Scand* 2017; **96**: 395–409.
76. Simchen MJ, Alkazaleh F, Adamson SL, Windrim R, Telford J, Beyene J, Kingdom J. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. *Am J Obstet Gynecol* 2004; **190**: 296–304.
77. Wolf HT, Huusom LD, Henriksen TB, Hegaard HK, Brok J, Pinborg A. Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis. *BJOG* 2020. DOI: 10.1111/1471-0528.16238.
78. Antenatal Magnesium Sulfate for Neuroprotection Guideline Development Panel. Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child. Adelaide: University of Adelaide, Australia 2010. <https://cdn.auckland.ac.nz/assets/liggins/docs/Antenatal%20magnesium%20sulphate%20prior%20to%20preterm%20birth%20for%20neuroprotection%20of%20the%20fetus,%20infant%20&%20child,%20National%20clinical%20practice%20guidelines.pdf>
79. Stockley EL, Ting JY, Kingdom JC, McDonald SD, Barrett JF, Synnes AR, Monterrosa L, Shah PS; Canadian Neonatal Network; Canadian Neonatal Follow-up Network; Canadian Preterm Birth Network Investigators. Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses. *Am J Obstet Gynecol* 2018; **219**: 606.e1–8.
80. GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. *BJOG* 2003; **110**: 27–32.
81. Thornton JG, Hornbuckle J, Vail A, Spiegelhalter DJ, Levene M; GRIT study group. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. *Lancet* 2004; **364**: 513–520.
82. Walker DM, Marlow N, Upstone L, Gross H, Hornbuckle J, Vail A, Wolke D, Thornton JG. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. *Am J Obstet Gynecol* 2011; **204**: 34.e1–9.
83. Lees CC, Marlow N, van Wassenae-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, Calvert S, Derks JB, Diemert A, Duvekot JJ, Ferrazzi E, Frusca T, Ganzevoort W, Hecher K, Martinelli P, Ostermayer E, Papageorgiou AT, Schlenbach D, Schneider KT, Thilaganathan B, Todros T, Valcamonic A, Visser GH, Wolf H; TRUFFLE study group. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. *Lancet* 2015; **385**: 2162–2172.
84. Parra-Saavedra M, Crovetto F, Triunfo S, Savchev S, Peguero A, Nadal A, Parra G, Gratacos E, Figueras F. Placental findings in late-onset SGA births without Doppler signs of placental insufficiency. *Placenta* 2013; **34**: 1136–1141.
85. Parra-Saavedra M, Crovetto F, Triunfo S, Savchev S, Parra G, Sanz M, Gratacos E, Figueras F. Added value of umbilical vein flow as a predictor of perinatal outcome in term small-for-gestational-age fetuses. *Ultrasound Obstet Gynecol* 2013; **42**: 189–195.
86. Stampalija T, Thornton J, Marlow N, Napolitano R, Bhida A, Pickles T, Bilardo CM, Gordijn SJ, Gyselaers W, Valensise H, Hecher K, Sande RK, Lindgren P, Bergman E, Arabin B, Breeze AC, Wee L, Ganzevoort W, Richter J, Berger A, Brodzki J, Derks J, Mecacci F, Maruotti GM, Mykkestad K, Lobmaier SM, Prefumo F, Klaritsch P, Calda P, Ebbing C, Frusca T, Raio L, Visser GHA, Krofta L, Cetin I, Ferrazzi E, Cesari E, Wolf H, Lees CC; on behalf of the TRUFFLE-2 Group. Fetal cerebral Doppler changes and outcome in late preterm fetal growth restriction: prospective cohort study. *Ultrasound Obstet Gynecol* 2020; **56**: 173–181.
87. Cruz-Mart nez R, Figueras F, Hernandez-Andrade E, Oros D, Gratacos E. Fetal brain Doppler to predict cesarean delivery for nonreassuring fetal status in term small-for-gestational-age fetuses. *Obstet Gynecol* 2011; **117**: 618–626.
88. Severi FM, Bocchi C, Visentin A, Falco P, Cobellis L, Florio P, Zagonari S, Pili G. Uterine and fetal cerebral Doppler predict the outcome of third-trimester small-for-gestational age fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol* 2002; **19**: 225–228.
89. Hershkovitz R, Kingdom JC, Geary M, Rodeck CH. Fetal cerebral blood flow redistribution in late gestation: identification of compromise in small fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol* 2000; **15**: 209–212.
90. Oros D, Figueras F, Cruz-Mart nez R, Padilla N, Meler E, Hernandez-Andrade E, Gratacos E. Middle versus anterior cerebral artery Doppler for the prediction of perinatal outcome and neonatal neurobehavior in term small-for-gestational-age fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol* 2010; **35**: 456–461.
91. Eixarch E, Meler E, Iraola A, Illa M, Crispi F, Hernandez-Andrade E, Gratacos E, Figueras F. Neurodevelopmental outcome in 2-year-old infants who were small-for-gestational age term fetuses with cerebral blood flow redistribution. *Ultrasound Obstet Gynecol* 2008; **32**: 894–899.
92. Odiibo AO, Riddick C, Pare E, Stamilio DM, Macones GA. Cerebroplacental Doppler ratio and adverse perinatal outcomes in intrauterine growth restriction: evaluating the impact of using gestational age-specific reference values. *J Ultrasound Med* 2005; **24**: 1223–1228.
93. Gramellini D, Folli MC, Raboni S, Vadora E, Meriardi A. Cerebral-umbilical Doppler ratio as a predictor of adverse perinatal outcome. *Obstet Gynecol* 1992; **79**: 416–420.
94. Habek D, Salihagi  A, Jugovi  D, Herman R. Doppler cerebro-umbilical ratio and fetal biophysical profile in the assessment of peripartur cardiotocography in growth-retarded fetuses. *Fetal Diagn Ther* 2007; **22**: 452–456.
95. Savchev S, Figueras F, Cruz-Mart nez R, Illa M, Botet F, Gratacos E. Estimated weight centile as a predictor of perinatal outcome in small-for-gestational-age pregnancies with normal fetal and maternal Doppler indices. *Ultrasound Obstet Gynecol* 2012; **39**: 299–303.
96. Murray E, Fernandes M, Fazel M, Kennedy SH, Villar J, Stein A. Differential effect of intrauterine growth restriction on childhood neurodevelopment: a systematic review. *BJOG* 2015; **122**: 1062–1072.
97. Arcangeli T, Thilaganathan B, Hooper R, Khan KS, Bhida A. Neurodevelopmental delay in small babies at term: a systematic review. *Ultrasound Obstet Gynecol* 2012; **40**: 267–275.
98. Van Wassenae-Leemhuis AG, Marlow N, Lees C, Wolf H; TRUFFLE investigators. The association of neonatal morbidity with long-term neurological outcome in infants who were growth restricted and preterm at birth: secondary analyses from TRUFFLE (Trial of Randomized Umbilical and Fetal Flow in Europe). *BJOG* 2017; **124**: 1072–1078.
99. Caradeux J, Martinez-Portilla RJ, Peguero A, Sotiriadis A, Figueras F. Diagnostic performance of third-trimester ultrasound for the prediction of late-onset fetal growth restriction: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2019; **220**: 449–459.e19.
100. Mallard EC, Williams CE, Johnston BM, Gluckman PD. Increased vulnerability to neuronal damage after umbilical cord occlusion in fetal sheep with advancing gestation. *Am J Obstet Gynecol* 1994; **170**: 206–214.
101. Figueras F, Fernandez S, Eixarch E, Gomez O, Martinez JM, Puerto B, Gratacos E. Middle cerebral artery pulsatility index: reliability at different sampling sites. *Ultrasound Obstet Gynecol* 2006; **28**: 809–813.
102. Boers KE, Vijgen SM, Bijlenga D, van der Post JA, Bekedam DJ, Kwee A, van der Salm PC, van Pampus MG, Spaanderdame ME, de Boer K, Duvekot JJ, Bremer HA, Hasaart TH, Delemarre FM, Bloemenkamp KW, van Meir CA, Willekes C, Wijnen EJ, Rijken M, le Cessie S, Roumen FJ, Thornton JG, van Lith JM, Mol BW, Scherjon SA; DIGITAT study group. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). *BMJ* 2010; **341**: c7087.
103. van Wyk L, Boers KE, van der Post JA, van Pampus MG, van Wassenae AG, van Baar AL, Spaanderdame ME, Becker JH, Kwee A, Duvekot JJ, Bremer HA, Delemarre FM, Bloemenkamp KW, de Groot CJ, Willekes C, Roumen FJ, van Lith JM, Mol BW, le Cessie S, Scherjon SA; DIGITAT Study Group. Effects on (neuro)developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial. *Am J Obstet Gynecol* 2012; **206**: 406.e1–7.
104. Boers KE, van Wyk L, van der Post JA, Kwee A, van Pampus MG, Spaanderdame ME, Duvekot JJ, Bremer HA, Delemarre FM, Bloemenkamp KW, de Groot CJ, Willekes C, Rijken M, Roumen FJ, Thornton JG, van Lith JM, Mol BW, le Cessie S, Scherjon SA; DIGITAT Study Group. Neonatal morbidity after induction vs expectant monitoring in intrauterine growth restriction at term: a subanalysis of the DIGITAT RCT. *Am J Obstet Gynecol* 2012; **206**: 344.e1–7.
105. Savchev S, Figueras F, Gratacos E. Survey on the current trends in managing intrauterine growth restriction. *Fetal Diagn Ther* 2014; **36**: 129–135.
106. Meher S, Hernandez-Andrade E, Basheer SN, Lees C. Impact of cerebral redistribution on neurodevelopmental outcome in small-for-gestational-age or growth-restricted babies: a systematic review. *Ultrasound Obstet Gynecol* 2015; **46**: 398–404.
107. Hernandez-Andrade E, Stampalija T, Figueras F. Cerebral blood flow studies in the diagnosis and management of intrauterine growth restriction. *Curr Opin Obstet Gynecol* 2013; **25**: 138–144.
108. DeVore GR. The importance of the cerebroplacental ratio in the evaluation of fetal well-being in SGA and AGA fetuses. *Am J Obstet Gynecol* 2015; **213**: 5–15.
109. Gardosi J, Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles. *Am J Obstet Gynecol* 2009; **201**: 28.e1–8.
110. Paules C, Dantas AP, Miranda J, Crovetto F, Eixarch E, Rodriguez-Sureda V, Dominguez C, Casu G, Rovira C, Nadal A, Crispi F, Gratacos E. Premature placental aging in term small-for-gestational-age and growth-restricted fetuses. *Ultrasound Obstet Gynecol* 2019; **53**: 615–622.
111. Parra-Saavedra M, Simeone S, Triunfo S, Crovetto F, Botet F, Nadal A, Gratacos E, Figueras F. Correlation between histological signs of placental underperfusion and perinatal morbidity in late-onset small-for-gestational-age fetuses. *Ultrasound Obstet Gynecol* 2015; **45**: 149–155.
112. Zhu MY, Milligan N, Keating S, Windrim R, Keunen J, Thakur V, Ohman A, Portnoy S, Sled JG, Kelly E, Yoo SJ, Gross-Wortmann L, Jaeggi E, Macgowan CK, Kingdom JC, Seed M. The hemodynamics of late-onset intrauterine growth restriction by MRI. *Am J Obstet Gynecol* 2016; **214**: 367.e1–17.
113. Roberts LA, Ling HZ, Poon LC, Nicolaides KH, Kametas NA. Maternal hemodynamics, fetal biometry and Doppler indices in pregnancies followed up for suspected fetal growth restriction. *Ultrasound Obstet Gynecol* 2018; **52**: 507–514.
114. Cruz-Mart nez R, Savchev S, Cruz-Lemini M, Mendez A, Gratacos E, Figueras F. Clinical utility of third-trimester uterine artery Doppler in the

- prediction of brain hemodynamic deterioration and adverse perinatal outcome in small-for-gestational-age fetuses. *Ultrasound Obstet Gynecol* 2015; 45: 273–278.
115. McCowan LM, Harding JE, Roberts AB, Barker SE, Ford C, Stewart AW. A pilot randomized controlled trial of two regimens of fetal surveillance for small-for-gestational-age fetuses with normal results of umbilical artery doppler velocimetry. *Am J Obstet Gynecol* 2000; 182: 81–86.
  116. Knight HE, Cromwell DA, Guroi-Urganci I, Harron K, van der Meulen JH, Smith GCS. Perinatal mortality associated with induction of labour versus expectant management in nulliparous women aged 35 years or over: An English national cohort study. *PLoS Med* 2017; 14: e1002425.
  117. Stock SJ, Ferguson E, Duffy A, Ford I, Chalmers J, Norman JE. Outcomes of elective induction of labour compared with expectant management: population based study. *BMJ* 2012; 344: e2838.
  118. Walker KF, Bugg GJ, Macpherson M, McCormick C, Grace N, Wildsmith C, Bradshaw L, Smith GC, Thornton JG; 35/39 Trial Group. Randomized Trial of Labor Induction in Women 35 Years of Age or Older. *N Engl J Med* 2016; 374: 813–822.
  119. Grobman WA, Rice MM, Reddy UM, Tita ATN, Silver RM, Mallett G, Hill K, Thom EA, El-Sayed YY, Perez-Delboy A, Rouse DJ, Saade GR, Boggess KA, Chauhan SP, Iams JD, Chien EK, Casey BM, Gibbs RS, Srinivas SK, Swamy GK, Simhan HN, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. *N Engl J Med* 2018; 379: 513–523.
  120. Cheng YW, Kaimal AJ, Snowden JM, Nicholson JM, Caughey AB. Induction of labor compared to expectant management in low-risk women and associated perinatal outcomes. *Am J Obstet Gynecol* 2012; 207: 502.e1–8.
  121. Crispi F, Figueras F, Cruz-Lemini M, Bartrons J, Bijns B, Gratacos E. Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity. *Am J Obstet Gynecol* 2012; 207: 121.e1–9.
  122. Stampalija T, Casati D, Monasta L, Sassi R, Rivolta MW, Muggiasca ML, Bauer A, Ferrazzi E. Brain sparing effect in growth-restricted fetuses is associated with decreased cardiac acceleration and deceleration capacities: a case-control study. *BJOG* 2016; 123: 1947–1954.
  123. Rigano S, Bozzo M, Ferrazzi E, Bellotti M, Battaglia FC, Galan HL. Early and persistent reduction in umbilical vein blood flow in the growth-restricted fetus: a longitudinal study. *Am J Obstet Gynecol* 2001; 185: 834–838.
  124. Ferrazzi E, Rigano S, Padoan A, Boito S, Pennati G, Galan HL. Uterine artery blood flow volume in pregnant women with an abnormal pulsatility index of the uterine arteries delivering normal or intrauterine growth restricted newborns. *Placenta* 2011; 32: 487–492.
  125. Spencer R, Ambler G, Brodzki J, Diemert A, Figueras F, Gratacos E, Hansson SR, Hecher K, Huertas-Ceballos A, Marlow N, Marsál K, Morsing E, Peebles D, Rossi C, Sebire NJ, Timms JF, David AL; EVEREST Consortium. EVEREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. *BMC Pregnancy Childbirth* 2017; 17: 43.
  126. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med* 2006; 355: 992–1005.
  127. Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorgiou AT, Alfirevic Z; STRIDER group. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. *Lancet Child Adolesc Health* 2018; 2: 93–102.
  128. Groom KM, McCowan LM, Mackay LK, Lee AC, Gardener G, Unterscheider J, Sekar R, Dickinson JE, Muller P, Reid RA, Watson D, Welsh A, Marlow J, Walker SP, Hyett J, Morris J, Stone PR, Baker PN. STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction. *BJOG* 2019; 126: 997–1006.
  129. Groom KM, Ganzevoort W, Alfirevic Z, Lim K, Papageorgiou AT; STRIDER Consortium. Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. *Ultrasound Obstet Gynecol* 2018; 52: 295–296.
  130. Valensise H, Vasapollo B, Novelli GP, Giorgi G, Verallo P, Galante A, Arduini D. Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery. *Ultrasound Obstet Gynecol* 2008; 31: 55–64.

## APPENDIX 1 Levels of evidence and grades of recommendation used in ISUOG Guidelines

### Classification of evidence levels

1++	High-quality meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with very low risk of bias
1+	Well-conducted meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with low risk of bias
1–	Meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with high risk of bias
2++	High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with very low risk of confounding, bias or chance and high probability that the relationship is causal
2+	Well-conducted case–control or cohort studies with low risk of confounding, bias or chance and moderate probability that the relationship is causal
2–	Case–control or cohort studies with high risk of confounding, bias or chance and significant risk that the relationship is not causal
3	Non-analytical studies, e.g. case reports, case series
4	Expert opinion

### Grades of recommendation

A	At least one meta-analysis, systematic review or randomized controlled trial rated as 1++ and directly applicable to the target population; or systematic review of randomized controlled trials or body of evidence consisting principally of studies rated as 1+ applicable directly to the target population and demonstrating overall consistency of results
B	Body of evidence including studies rated as 2++ applicable directly to the target population and demonstrating overall consistency of results; or evidence extrapolated from studies rated as 1++ or 1+
C	Body of evidence including studies rated as 2+ applicable directly to the target population and demonstrating overall consistency of results; or evidence extrapolated from studies rated as 2++
D	Evidence of level 3 or 4; or evidence extrapolated from studies rated as 2+
Good practice point	Recommended best practice based on clinical experience of the Guideline Development Group

## SUPPORTING INFORMATION ON THE INTERNET

The following supporting information may be found in the online version of this article:



**Table S1** Most relevant studies reporting reference ranges for fetal middle cerebral artery (MCA), cerebroplacental ratio (CPR) and umbilicocerebral ratio (UCR). Adapted from Ruiz-Martinez *et al.*<sup>47</sup>